Effect of early intravenous recombinant human brain natriuretic peptide combined with noninvasive positive pressure ventilation in the treatment of acute decompensated heart failure

Objective:To investigate the clinical effects of early intravenous infusion recombinant human brain natriuretic peptide (rhBNP) combined with noninvasive positive pressure ventilation(NIPPV) in the treatment of patients with decompensated acute heart failure.Methods:The clinical data including age,gender,past medical history,N-terminal pro-brain natriuretic peptide(NT-proBNP) at 1,2,3,5,7 and 10 days after hospitalization,oxygenation index and the time of NIPPV of 112 patients with decompensated acute heart failure were retrospectively analyzed.All patients were divided into drug group and control group according to whether the rhBNP was used.NT-proBNP,oxygenation index and the time of NIPPV in two groups were compared.According to the results of multivariate regression analysis,the fitting curve were drawed,the relativity between the variance ratio of NT-proBNP and oxygenation index and the time of NIPPV were analyzed.Results:The falling NT-proBNP level and rising oxygenation index level in drug group were higher than those in control group(P 0.01).Multivariate regression analysis showed that ageodds ratio(OＲ) = 1.174,95%,95% CI(1.797 to 1.910),P 0.01,the variance ratio of NT-proBNPOＲ = 1.363,95% CI(1.936 to 2.358),P 0.05 and the variance ratio of oxygenation indexOＲ = 2.088,95%CI(1.273 to 1.847),P 0.05were correlated to the time of NIPPV.The variance ratio of NTproBNP and oxygenation index,and the time of NIPPV in fitting curve showed linear correlation(P 0.05).Conclusions:Early intravenous infusion recombinant rhBNP combined with NIPPV in the treatment of patients with decompensated acute heart failure can decrease the level of NT-proBNP,increase oxygenation index and short the time of NIVPPV,which can obviously improve the outcome of the patients.